 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...6061626364656667686970...8687» |
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Multicentric Carpotarsal Osteolysis Syndrome (MCTO) Has a Generalized High Turnover Bone Phenotype, High S RANKL and Responds to Denosumab (ENDOExpo, Booth 425) - Apr 1, 2020 - Abstract #ENDO2020ENDO_4333;
Conclusions/Clinical Lessons : MCTO (MAFB, mutation c.206C>T,p.Ser69Leu), has a generalized high turnover skeletal phenotype (osteoporosis), likely driven by very high levels of sRANKL. Denosumab is a targeted treatment for the osteoporosis, which may help stabilize the osteolysis.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Multicentric Carpotarsal Osteolysis Syndrome (MCTO) Has a Generalized High Turnover Bone Phenotype, High S RANKL and Responds to Denosumab (ENDOExpo) - Apr 1, 2020 - Abstract #ENDO2020ENDO_4212;
Conclusions/Clinical Lessons : MCTO (MAFB, mutation c.206C>T,p.Ser69Leu), has a generalized high turnover skeletal phenotype (osteoporosis), likely driven by very high levels of sRANKL. Denosumab is a targeted treatment for the osteoporosis, which may help stabilize the osteolysis.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis (ENDOExpo, Booth 425) - Apr 1, 2020 - Abstract #ENDO2020ENDO_4134;
Patients previously on teriparatide treatment present alterations of the relative expression of miRs related to the expression of key osteoblastic genes such as RUNX-2 (miR-23), collagen type 1 (miR-29a) and HDAC5 gene (miR-2861) during subsequent treatment with Dmab . Our data suggest that teriparatide may influence the subsequent anti-resorptive effect of Dmab on bone metabolism at post-transcriptional level.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis (ENDOExpo) - Apr 1, 2020 - Abstract #ENDO2020ENDO_4061;
Patients previously on teriparatide treatment present alterations of the relative expression of miRs related to the expression of key osteoblastic genes such as RUNX-2 (miR-23), collagen type 1 (miR-29a) and HDAC5 gene (miR-2861) during subsequent treatment with Dmab . Our data suggest that teriparatide may influence the subsequent anti-resorptive effect of Dmab on bone metabolism at post-transcriptional level.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg., Bonrise (ibandronate sodium) / Elder Pharma
Teriparatide and Its Bone Healing Power (ENDOExpo) - Apr 1, 2020 - Abstract #ENDO2020ENDO_3734;
There are a limited number of cases reported in regards to teriparatide induced healing of non-osteoporotic fractures (3). Our case is one of the very few reported to have shown complete radiographic and clinical healing of a traumatic, non-osteoporotic fracture after use of teriparatide for 12 weeks.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
RANKL Is a Novel Regulator of Male Reproductive Function (Room 154) - Apr 1, 2020 - Abstract #ENDO2020ENDO_3589;
Moreover, men with high baseline serum OPG or Inhibin B concentrations experienced an increase in the number of progressive motile sperm 80 days after Denosumab injection. In conclusion, this translational study demonstrates that RANKL is a novel regulator of male reproductive function.
- | Prolia (denosumab) / Amgen, Kineret (anakinra) / SOBI
Enrollment change, Combination therapy, Metastases: NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) - Mar 31, 2020
P1, N=57, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
In conclusion, this translational study demonstrates that RANKL is a novel regulator of male reproductive function. N=147 --> 57
- | Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: DenosuMast: Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis (clinicaltrials.gov) - Mar 31, 2020
P3, N=90, Recruiting, Sponsor: Assistance Publique - H
N=147 --> 57 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2021 --> Mar 2024
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: Medication-related Osteonecrosis of the Jaw: A Literature Review. (Pubmed Central) - Mar 29, 2020
There is limited scientific evidence regarding the relationship between MRONJ and older age. Further ONJ-related research on the aging population is required to manage the treatment of such diseases in older people in the future.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: Giant cell tumor of bone : Morphology, molecular pathogenesis, and differential diagnosis (Pubmed Central) - Mar 28, 2020
Therefore, the RANKL inhibitor denosumab constituted an essential element for giant cell tumor therapy over the last several years, as it blocks the maturation of osteoclasts and thus the osteolytic activity and the spread of tumor...Giant cell osteosarcomas rarely contain H3F3A mutations. Chondroblastoma is characterized by mutations in the H3F3B gene.
- paclitaxel / Generic mfg.
Renal Phosphate Wasting due to Tumor-Induced Osteomalacia in a Breast Cancer Patient () - Mar 27, 2020 - Abstract #NKFCSM2020NKF_CSM_164;
TIO is an important differential, in that early detection may result in improved outcomes. FGF23 testing is becoming more available in the clinical setting, and may help with detection of TIO.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: Stopping Denosumab. (Pubmed Central) - Mar 26, 2020
As denosumab discontinuation is characterized by many uncertainties, denosumab is a second-line treatment for osteoporosis. Studies are urgently needed to define the management of denosumab discontinuation.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evomate (raloxifene hydrochloride) / Shreya Life Sciences
Clinical, Review, Journal: Mechanisms Underlying Normal Fracture Healing and Risk Factors for Delayed Healing. (Pubmed Central) - Mar 26, 2020
Interest is high for exploring currently available osteoporosis therapies for efficacy in fracture repair. Definitive data supporting their efficacy are essential in achieving approval for this indication.
- | Prolia (denosumab) / Amgen, NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: SALTIRE II: Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis. (clinicaltrials.gov) - Mar 26, 2020
P2, N=152, Completed, Sponsor: University of Edinburgh
Definitive data supporting their efficacy are essential in achieving approval for this indication. Recruiting --> Completed | Trial completion date: Aug 2017 --> Nov 2019 | Trial primary completion date: Aug 2017 --> Nov 2019
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial suspension, Metastases: LENVOS: Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (clinicaltrials.gov) - Mar 25, 2020
P2, N=35, Suspended, Sponsor: Centre Leon Berard
Recruiting --> Completed | Trial completion date: Aug 2017 --> Nov 2019 | Trial primary completion date: Aug 2017 --> Nov 2019 Recruiting --> Suspended
- | Prolia (denosumab) / Amgen
Enrollment closed: MOSCAR: Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies (clinicaltrials.gov) - Mar 25, 2020
P3, N=216, Active, not recruiting, Sponsor: Centre Leon Berard
Recruiting --> Suspended Recruiting --> Active, not recruiting
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Retrospective data, Review, Journal: Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis. (Pubmed Central) - Mar 24, 2020
From baseline to post-treatment, there are no differences in serum Ca and PTH. However, mild hypocalcemia can occur following denosumab treatment, requiring monitoring and titration of Ca and vitamin D supplements.
- | Tecfidera (dimethyl fumarate) / Biogen
Journal: Dimethyl fumarate-associated transient bone marrow oedema syndrome. (Pubmed Central) - Mar 23, 2020
In this instance of DMF-associated bone marrow oedema, cessation of DMF and treatment with denosumab resulted in symptomatic improvement. DMF therapy may potentially result in bone marrow oedema due to inhibition of common upstream signalling pathways, including the Nrf2 signalling pathway.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Denosumab and lichen planus: Two cases (e-Poster Hall) - Mar 21, 2020 - Abstract #EADVSp2020EADV-Sp_82;
- | Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
Journal: Dense sclerotic metaphyseal bands caused by denosumab therapy. (Pubmed Central) - Mar 21, 2020
DMF therapy may potentially result in bone marrow oedema due to inhibition of common upstream signalling pathways, including the Nrf2 signalling pathway. No abstract available
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: Medication-related Osteonecrosis of the Jaw: A Review. (Pubmed Central) - Mar 21, 2020
Antiresorptive medications such as bisphosphonate and denosumab are currently considered the treatment of choice in patients with osteoclastic bone disease...As a preventive measure, dental screening before initiating any type of ONJ-related medications can significantly lower the risk of ONJ. Treatment goals can be achieved through pain and infection control, in addition to the management of bone necrosis and resorption. The aim of this review is to identify all causative agents and summarize the preventive measures, diagnostic criteria, and treatment strategies related to MRONJ.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review. (Pubmed Central) - Mar 21, 2020
A systematic search was conducted and relevant studies that evaluated the influence of osteoporosis medications (bisphosphonates [BPs], denosumab, selective estrogen receptor modulators [SERMs], recombinant human parathyroid hormone teriparatide [TPTD], and strontium ranelate [SrR]) on wrist, hip, and spine fracture healing, were selected...In spine fracture, controversy exists for the role of each medication to the fracture stability, but several studies reported that fracture site pain was better in TPTD treated patients than BPs treated patients. Considering no clinical data of negative fracture healing of the antiresorptive medication and the danger of subsequent fracture after initial osteoporotic fracture, there is no evidence to delay initiation of osteoporosis medications after fracture.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. (Pubmed Central) - Mar 20, 2020
The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Retrospective data, Journal: High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. (Pubmed Central) - Mar 18, 2020
Most (n = 251) patients were recommended to treat by the GIOP guideline (scores ≥ 3); bisphosphonates, denosumab, teriparatide, or active vitamin D was prescribed for 85.7%...Our single-center study found that bisphosphonates were commonly used long term by Japanese patients with SLE. As AFF is not rare, AFF should be cared in patients with SLE.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal, Adverse events: Medicaments and oral healthcare. Adverse effects of medicaments: the 'Big Five' of bone healing (Pubmed Central) - Mar 17, 2020
By recognising the correct patient group, dentists can ask appropriate questions about the use of medicaments in the present or in the past. A dentist can recognise patients with a risk of medication-related osteonecrosis by using this method.
- | Prolia (denosumab) / Amgen
Trial completion date, Trial initiation date, Trial primary completion date: Markers of Osteoporosis in Cystic Fibrosis (clinicaltrials.gov) - Mar 16, 2020
P4, N=100, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
A dentist can recognise patients with a risk of medication-related osteonecrosis by using this method. Trial completion date: Jul 2026 --> Jul 2027 | Initiation date: Dec 2019 --> Dec 2020 | Trial primary completion date: Jul 2026 --> Jul 2027
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Denosumab-Related Mononeuritis Leading to Diaphragm and Long Thoracic Nerve Paralysis (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) - Mar 15, 2020 - Abstract #ATS2020ATS_10325;
Interestingly, RANKL is present in endothelial cells and lymphocytes, suggesting a possible mechanism for immune-system-mediated neurological pathology. As the use of monoclonal antibodies increases, physicians should be aware of possible neurological complications.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study (clinicaltrials.gov) - Mar 13, 2020
P1, N=75, Active, not recruiting, Sponsor: Massachusetts General Hospital
As the use of monoclonal antibodies increases, physicians should be aware of possible neurological complications. Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evenity (romosozumab) / Astellas, Amgen, UCB
Clinical, Journal: Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. (Pubmed Central) - Mar 12, 2020
P3
Efficacy and safety for romosozumab-to-denosumab were similar between Japanese women and the overall population. The sequence of romosozumab to rebuild the skeletal foundation before transitioning to antiresorptive treatment with denosumab is a promising regimen for Japanese postmenopausal women with osteoporosis at high risk of fracture.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Management of osteoporosis in the Middle East and North Africa: a survey of physicians' perceptions and practices. (Pubmed Central) - Mar 12, 2020
The sequence of romosozumab to rebuild the skeletal foundation before transitioning to antiresorptive treatment with denosumab is a promising regimen for Japanese postmenopausal women with osteoporosis at high risk of fracture. This first look at physicians' practice patterns on the diagnosis and treatment of osteoporosis in the MENA region underscores the pressing need for an official call for action, at all levels, to address this large care gap.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Henlius Reports the NMPA’s Acceptance of IND for HLX14 (biosimilar, denosumab) https://t.co/jNHqAhUn9P (Twitter) - Mar 12, 2020
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: Bone metastases in thyroid cancer. (Pubmed Central) - Mar 11, 2020
Emerging data also suggest that treatments such as multikinase inhibitors (MKIs) can be less effective in controlling bone, as opposed to other (e.g. lung), metastases in thyroid cancers, making special attention to bone critical even in the setting of active MKI therapy. Although locoregional therapies including surgery, radiotherapy and ablation play important roles in palliation, antiresorptive agents including bisphosphonates and denosumab appear individually to delay and/or lessen skeletal morbidity and complications, with dosing frequency of every 3 months appearing optimal; their early application should therefore be strongly considered.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal, Real-World Evidence: Real World Experience of Denosumab Treatment in the Belfast Osteoporosis Service. (Pubmed Central) - Mar 10, 2020
There has been recent progress with adoption of shared care administration in primary care. As part of a quality improvement programme we have recently developed a dedicated denosumab database and day-case treatment clinic for those receiving treatment in secondary care.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg., Asahi Kasei
Prescribing Practices of Denosumab and Zoledronic Acid in Breast and Prostate Cancer at The University of Chicago Medicine () - Mar 9, 2020 - Abstract #HOPA2020HOPA_339;
The most common reason for the lower adherence rate in denosumab groups was scheduling convenience. During the study period, there were 3, 1, 2 and 4 patients had SREs in the above four groups respectively.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Laboratory Monitoring for Denosumab in Solid Tumor Patients with Bone Metastases at an Academic Medical Center () - Mar 9, 2020 - Abstract #HOPA2020HOPA_311;
Bone modifying agents such as zoledronic acid and denosumab are recommended to prevent skeletal related events (SREs). The purpose of this project is to design an institutional guideline to optimize calcium and phosphorous monitoring in patients with solid tumors receiving denosumab.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Implementation of a Standardized Process Addressing Dental Care Amongst Patients Receiving Antiresorptive Therapy: A Quality Improvement Project () - Mar 9, 2020 - Abstract #HOPA2020HOPA_293;
Data collection is currently ongoing for this project. Results will be presented at the 2020 HOPA annual conference.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Antiresorptive Bone Therapy Use in Advanced Lung Cancer and Associated Outcomes () - Mar 9, 2020 - Abstract #HOPA2020HOPA_150;
[5,6] The prognosis of advanced lung cancer has improved significantly since these trials were conducted, and the utilization of denosumab has not been evaluated...Conclusions In progress. Pending completion prior to presentation.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] INTEGRATION OF QUANTITATIVE SYSTEMS PHARMACOLOGY AND HEALTH ECONOMICS MODELS FOR DRUG DEVELOPMENT DECISION MAKING- APPLICATION TO TREATMENT OF SKELETAL RELATED EVENTS IN PATIENTS WITH BONE METASTASES () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_756;
METHODS The QSP of denosumab (DMB) and a hypothetical novel bone therapeutic (Drug X) were described based on a previously developed multi-scale physiologic model for bone...Simulations of Drug X at the 4 week interval did not result in an improvement in QALY, while the 16 week interval resulted in insufficient effects on BMD and fracture rate and reduced QALY relative to DMB. CONCLUSIONS This proof of concept simulation study demonstrated the potential utility of linking a quantitative understanding of pharmacology with mathematical models of cost-effectiveness for the purpose of informing early clinical development.
- Xofigo (radium Ra-223 dichloride) / Bayer
[VIRTUAL] REAL-WORLD TREATMENT PATTERNS OF RADIUM-223 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER RECEIVING CARE AT A US TERTIARY ONCOLOGY CENTER () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_654;
Overall, 122 (55.5%) patients received a bone-targeting agent following mCRPC, including zoledronic acid (31.4%) and denosumab (22.7%)...OS was similar between groups receiving radium-223 pre- vs. post-chemotherapy and with or without combination hormonal therapy. Understanding real world treatment patterns of radium-223 use will be critical to optimizing therapy for patients.
- Soliris (eculizumab) / Alexion Pharma, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] THE EFFECTS OF WHITE AND BROWN BAGGING OF PHYSICIAN-ADMINISTERED DRUGS ON SPENDING AND OUT-OF-POCKET COSTS IN MEDICARE () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_119;
For beneficiaries who did not receive the low-income subsidy, median out-of-pocket spending when comparing Part D out-of-pocket costs to the 20% co-pay for Part B ranged from $5 lower for denosumab to $5,563 lower for eculizumab; however, beneficiaries may have supplemental insurance that would reduce their Part B out-of-pocket costs. For beneficiaries who receive physician-administered drugs, selecting a Part D plan with a low co-pay for their drug regimen can offer savings compared to the 20% Part B co-insurance; however, white/brown-bagging places burden on beneficiaries to transport their drugs to an infusion center and may increase program spending.
- | Journal: Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. (Pubmed Central) - Mar 7, 2020
Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, P3 data, Journal: Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. (Pubmed Central) - Mar 5, 2020
A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies. Denosumab inhibits the progression of joint destruction, increases BMD and is well tolerated in patients with RA taking csDMARD.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] CLINICAL FEATURES ASSOCIATED WITH FRAGILITY FRACTURE AFTER DISCONTINUATION OF TREATMENT WITH DENOSUMAB: A CASE-CONTROL STUDY (Tan) - Mar 5, 2020 - Abstract #EULAR2020EULAR_1116;
Denosumab inhibits the progression of joint destruction, increases BMD and is well tolerated in patients with RA taking csDMARD. Sequential treatment with bisphosphonates and diagnosis of secondary osteoporosis are related to the absence of fractures after discontinuation of denosumab treatment.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: A MULTIVARIATE LINEAR REGRESSION ANALYSIS IDENTIFYING PREDICTIVE FACTORS FOR LOW BONE MASS (Poster Tour) - Mar 5, 2020 - Abstract #EULAR2020EULAR_1112;
Multivariate analyses corroborated low BMD to be predicted by traditional factors like age, female sex and menopause but showed current and well as life-time GC dose to be positively associated with BMD in our cohort of patients with chronic inflammatory rheumatic diseases. This suggests that optimal management of disease activity with GCs might be beneficial in order to avoid bone loss due to inflammation.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Denosumab for Reducing Risk of Fractures in Postmenopausal Women. (Pubmed Central) - Mar 4, 2020
This suggests that optimal management of disease activity with GCs might be beneficial in order to avoid bone loss due to inflammation. No abstract available
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Observational data, Journal: Uncertainty managing patients treated with antiresorptive drugs: a cross-sectional study of attitudes and self-reported behavior among dentists in Sweden. (Pubmed Central) - Mar 4, 2020
Dentists practicing in Sweden express a strong need for an improved level of knowledge when managing patients treated with bisphosphonates and denosumab. The results demonstrate a need for the necessary advancement of education and clinical training at dental schools in order to prepare dentists to provide safe, modern care within the healthcare sector.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, lithium / Generic mfg.
Journal: High Rate of Occult Urolithiasis in Normocalcemic Primary Hyperparathyroidism. (Pubmed Central) - Mar 4, 2020
The results demonstrate a need for the necessary advancement of education and clinical training at dental schools in order to prepare dentists to provide safe, modern care within the healthcare sector. We found a high prevalence of occult kidney stones in NPHPT patients, similar to what is observed in clinically manifested urolithiasis, in hypercalcemic PHPT.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab. (Pubmed Central) - Mar 4, 2020
In de novo KTR treated with 2 doses of denosumab, we detect a marked decrease in lumbar spine and hip BMD when denosumab is discontinued. Denosumab treatment should therefore not be discontinued without considering an alternative antiresorptive treatment.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] THERAPEUTIC APPROACHES TO OSTEOSARCOPENIA: DENOSUMAB EFFECT ON FALLS RISK, PHYSICAL PERFORMANCE AND WALKING SPEED (Bywaters) - Mar 4, 2020 - Abstract #EULAR2020EULAR_709;
Also, Denosumab, enhanced multidirectional agility as depicted by TUG. Collectively, this would explain the reduction of falls risk which got worse on stopping the medication.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] STUDY OF RISK OF VERTEBRAL FRACTURES AFTER THE WITHDRAWAL OF DENOSUMAB TREATMENT (Tan) - Mar 4, 2020 - Abstract #EULAR2020EULAR_602;
Fractured patients had lower BMD gain despite the treatment than non-fractured patients and also the loss of BMD at rest was greater, without significant differences probably due to low number of patients. Neither the presence of previous fractures nor the duration of treatment could be related to the presence of VF at rest.